What You Should Know:
– Starget Pharma, an innovative startup specializing in precision cancer diagnostics and targeted radiotherapy, has secured $5.1M in funding from Cancer Focus, a fund established in collaboration with the renowned MD Anderson Cancer Center.
– The investment will support Starget Pharma’s upcoming clinical trial for treating advanced metastatic cancers, including sarcomas, neuroendocrine tumors, melanoma, and liver cancer.
Revolutionizing Cancer Treatment with Targeted Radiotherapy
Starget Pharma, co-founded by CEO Sigal Clemenson-Kushnir and Chairman Ronen Clemenson, has raised a total of $15.1M to date. Starget Pharma, founded in 2019 through ARC Innovation, the innovation arm of Sheba Medical Center, is developing groundbreaking radioligand-based therapies. These therapies precisely target tumor cells with focused radiation, minimizing damage to surrounding healthy tissue and offering a safer and more effective alternative to traditional radiotherapy.
AI-Driven Platform for Personalized Cancer Care
Starget Pharma’s innovative platform combines diagnostic imaging with targeted radiotherapy to create personalized treatment plans for patients with advanced cancers. The platform’s AI-driven technology enables:
- Precise Targeting: Highly accurate delivery of radiation to tumor cells, minimizing damage to healthy tissue.
- Personalized Treatment: Tailored treatment plans based on individual patient needs and tumor characteristics.
- Improved Outcomes: Increased efficacy and reduced side effects compared to traditional radiotherapy.
Upcoming Clinical Trial
The new funding will support a clinical trial to evaluate the safety and efficacy of Starget Pharma’s targeted radiotherapy in treating various advanced cancers. The trial will be conducted at the University of Texas MD Anderson Cancer Center and other leading institutions, with patient recruitment expected to begin in early 2025.
“This investment highlights the potential of our radioligand-based technology to deliver safer and more effective treatments for complex cancers. We look forward to collaborating with MD Anderson in our upcoming clinical trial, where early studies have already demonstrated safety and strong tumor cell uptake. We believe our technology offers a significant alternative to existing therapies, particularly for patients facing advanced cancer with limited treatment options,” said CEO Sigal Clemenson-Kushnir.
